作者:Paolo Mellini、Vincenzo Carafa、Barbara Di Rienzo、Dante Rotili、Daniela De Vita、Roberto Cirilli、Bruno Gallinella、Donatella Paola Provvisiero、Salvatore Di Maro、Ettore Novellino、Lucia Altucci、Antonello Mai
DOI:10.1002/cmdc.201200318
日期:2012.11
The best of both: SIRT1/2 inhibitors were developed by combining chemical features of selisistat (SIRT1‐selective inhibitor; blue) and carprofen (anti‐inflammatory drug; red). The most potent compound (shown) increased acetyl‐p53 and acetyl‐α‐tubulin levels, and induced slight apoptosis at 50 μM in U937 cells, differently from selisistat and carprofen.
两者中的佼佼者: SIRT1 / 2抑制剂是通过将selisistat(SIRT1选择性抑制剂;蓝色)和卡洛芬(抗炎药;红色)的化学特征相结合而开发的。最有效的化合物(示出)增加乙酰化p53和乙酰α微管蛋白的水平,并诱导细胞凋亡轻微,在50μ中号在U937细胞中,不同于selisistat和卡洛芬。